Aims
Highly interdisciplinary research focused on the pre-clinical development of novel synthetic small organic molecules cancer therapeutics. Laboratory utilizing organic molecules synthesis for the development of anti-cancer therapeutic based on small molecules and peptide based targeted drug delivery system against different types of cancer.  Objective is to create a pathway which bridge between chemist and biologist to translate synthetic anticancer molecules for further validation against in vitro/in vivo model cancer model.  The work will be carried out with biologists and drug discovery chemist together for the development of novel targeted cancer therapeutics.

​

Latest News (Patent/publication in 2024-2025)

1.  "Synthetically developed DNA-targeting naphthalimide-artesunate derivatives and their tumoricidal effect." Indian Patent Granted. No. 506734, 2024

2. “Naphtalimide-Se-TMZ compound and a method of preparing the same”. Indian Patent Application. No. 202431048630 , 2024

3. S Sharma, R Roy, A Vartak, E Sen, UH Sk*, "Synthesis and characterization of a novel Naphthalimide-Selenium based Temozolomide drug conjugate in glioma cells". Bioorganic Chemistry, 2025, 154, 107998

4. D RoyMahapatra, R Singh, UH Sk*, PP Manna, "Engineered artesunate-naphthalimide hybrid dual drug for synergistic multimodal therapy against experimental murine lymphoma". Molecular Pharmaceutics 2024, 21 (3), 1090-1107

5. T Ria, R Roy, US Mandal, UH Sk*, "Prospects of nano-theranostic approaches against breast and cervical cancer". Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2024, 189227